Rafael Amado Sells 3,000 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB) insider Rafael Amado sold 3,000 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $38.41, for a total value of $115,230.00. Following the sale, the insider now directly owns 30,834 shares of the company’s stock, valued at approximately $1,184,333.94. This trade represents a 8.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Rafael Amado also recently made the following trade(s):

• On Tuesday, December 31st, Rafael Amado sold 7,583 shares of Zai Lab stock. The shares were sold at an average price of $26.28, for a total value of $199,281.24.

Zai Lab Stock Performance

Shares of ZLAB stock traded up $0.09 on Wednesday, hitting $38.01. The stock had a trading volume of 511,034 shares, compared to its average volume of 750,645. The stock’s 50 day moving average is $29.97 and its 200-day moving average is $27.45. The firm has a market capitalization of $4.17 billion, a price-to-earnings ratio of -13.72 and a beta of 1.08. Zai Lab Limited has a 52-week low of $13.48 and a 52-week high of $39.61.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.19). The firm had revenue of $109.07 million during the quarter, compared to analyst estimates of $110.15 million. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. Equities analysts expect that Zai Lab Limited will post -2.58 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new stake in Zai Lab during the 4th quarter worth approximately $29,000. Pictet Asset Management Holding SA acquired a new stake in shares of Zai Lab during the fourth quarter worth approximately $31,000. Barclays PLC increased its stake in shares of Zai Lab by 337.6% in the fourth quarter. Barclays PLC now owns 3,702 shares of the company’s stock worth $97,000 after buying an additional 2,856 shares during the last quarter. US Bancorp DE increased its stake in shares of Zai Lab by 1,671.9% in the fourth quarter. US Bancorp DE now owns 5,865 shares of the company’s stock worth $154,000 after buying an additional 5,534 shares during the last quarter. Finally, Jasper Ridge Partners L.P. acquired a new stake in Zai Lab in the fourth quarter valued at $210,000. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Analyst Upgrades and Downgrades

ZLAB has been the topic of several research reports. Bank of America restated a “neutral” rating and issued a $36.10 price target (up previously from $29.00) on shares of Zai Lab in a report on Monday, March 3rd. JPMorgan Chase & Co. lifted their target price on shares of Zai Lab from $44.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, March 13th. Cantor Fitzgerald upgraded Zai Lab to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, Scotiabank assumed coverage on Zai Lab in a research note on Friday, March 7th. They set a “sector outperform” rating and a $55.00 price objective on the stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.